The epidemiological signature of influenza B virus and its B/Victoria and B/Yamagata lineages in the 21st century
Autoři:
Saverio Caini aff001; Gabriela Kusznierz aff002; Verònica Vera Garate aff002; Sonam Wangchuk aff003; Binay Thapa aff003; Francisco José de Paula Júnior aff004; Walquiria Aparecida Ferreira de Almeida aff004; Richard Njouom aff005; Rodrigo A. Fasce aff006; Patricia Bustos aff006; Luzhao Feng aff007; Zhibin Peng aff007; Jenny Lara Araya aff008; Alfredo Bruno aff009; Doménica de Mora aff009; Mónica Jeannette Barahona de Gámez aff011; Richard Pebody aff012; Maria Zambon aff012; Rocio Higueros aff013; Rudevelinda Rivera aff014; Herman Kosasih aff015; Maria Rita Castrucci aff016; Antonino Bella aff017; Hervé A. Kadjo aff018; Coulibaly Daouda aff019; Ainash Makusheva aff020; Olga Bessonova aff021; Sandra S. Chaves aff022; Gideon O. Emukule aff023; Jean-Michel Heraud aff024; Norosoa H. Razanajatovo aff024; Amal Barakat aff025; Fatima El Falaki aff025; Adam Meijer aff026; Gé A. Donker aff001; Q. Sue Huang aff027; Tim Wood aff027; Angel Balmaseda aff028; Rakhee Palekar aff029; Brechla Moreno Arévalo aff030; Ana Paula Rodrigues aff031; Raquel Guiomar aff032; Vernon Jian Ming Lee aff033; Li Wei Ang aff033; Cheryl Cohen aff034; Florette Treurnicht aff034; Alla Mironenko aff036; Olha Holubka aff036; Joseph Bresee aff037; Lynnette Brammer aff022; Mai T. Q. Le aff038; Phuong V. M. Hoang aff038; Clotilde El Guerche-Séblain aff039; John Paget aff001;
Působiště autorů:
Netherlands Institute for Health Services Research (Nivel), Utrecht, The Netherlands
aff001; National Institute of Respiratory Diseases "Emilio Coni", Santa Fe, Argentina
aff002; Royal Centre for Disease Control, Department of Public Health, Ministry of Health, Thimphu, Bhutan
aff003; Ministry of Health, Department of Surveillance of Transmissible Diseases, Brasília/DF, Brazil
aff004; Virology Department, Centre Pasteur of Cameroon, Yaoundé, Cameroon
aff005; Sub-Department of Viral Diseases, Instituto de Salud Pública de Chile, Santiago, Chile
aff006; Division of Infectious Diseases, Chinese Center for Disease Control and Prevention, Beijing, P.R. China
aff007; National Influenza Center, Ministry of Health, San José, Costa Rica
aff008; National Institute of Public Health Research (INSPI), National Reference Centre for Influenza and Other Respiratory Viruses, Guayaquil, Ecuador
aff009; Agricultural University of Ecuador, Guayaquil, Ecuador
aff010; National Influenza Center, Ministry of Health, San Salvador, El Salvador
aff011; Public Health England, London, England, United Kingdom
aff012; National Influenza Center, Ministry of Health, Guatemala City, Guatemala
aff013; National Influenza Center, Ministry of Health, Tegucigalpa, Honduras
aff014; US Naval Medical Research Unit No.2, Jakarta, Indonesia
aff015; National Influenza Center, Department of Infectious Diseases, National Institute of Health, Rome, Italy
aff016; Department of Infectious Diseases, National Institute of Health, Rome, Italy
aff017; Department of Epidemic Virus, Institut Pasteur, Abidjan, Côte d'Ivoire
aff018; Service of Epidemiological Diseases Surveillance, National Institute of Public Hygiene, Abidjan, Côte d'Ivoire
aff019; National Center of Expertise, Committee of Public Health Protection, Ministry of Health, Astana, Kazakhstan
aff020; National Center of Expertise, Committee of Public Health Protection, Ministry of Health, Uralsk City, Kazakhstan
aff021; Influenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America
aff022; Influenza Program, Centers for Disease Control and Prevention, Nairobi, Kenya
aff023; National Influenza Center, Virology Unit, Institut Pasteur de Madagascar, Antananarivo, Madagascar
aff024; National Influenza Center, Institut National d'Hygiène, Ministry of Health, Rabat, Morocco
aff025; National Institute for Public Health and the Environment, Centre for Infectious Diseases Research, Diagnostics and Laboratory Surveillance, Bilthoven, The Netherlands
aff026; Institute of Environmental Science and Research, Weillngton, New Zealand
aff027; National Influenza Center, Ministry of Health, Managua, Nicaragua
aff028; Pan American Health Organization, Washington, District of Columbia, United States of America
aff029; National Influenza Center, IC Gorgas, Panama City, Panama
aff030; Department of epidemiology, National Institute of Health Doutor Ricardo Jorge, Lisbon, Portugal
aff031; National Influenza Reference Laboratory, National Institute of Health Doutor Ricardo Jorge, Lisbon, Portugal
aff032; Public Health Group, Ministry of Health, Singapore, Singapore
aff033; Centre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa
aff034; School of Public Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
aff035; L.V.Gromashevsky Institute of Epidemiology and Infectious Diseases, National Academy of Medical Science of Ukraine, Department of Respiratory and other Viral Infections, Kyiv, Ukraine
aff036; Influenza Division, National Center for Immunizations and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America
aff037; National Institute of Hygiene and Epidemiology, Hanoi, Vietnam
aff038; Global Vaccine Epidemiology and Modeling Department (VEM), Franchise Epidemiologist, Sanofi Pasteur, Lyon, France
aff039
Vyšlo v časopise:
PLoS ONE 14(9)
Kategorie:
Research Article
doi:
https://doi.org/10.1371/journal.pone.0222381
Souhrn
We describe the epidemiological characteristics, pattern of circulation, and geographical distribution of influenza B viruses and its lineages using data from the Global Influenza B Study. We included over 1.8 million influenza cases occurred in thirty-one countries during 2000–2018. We calculated the proportion of cases caused by influenza B and its lineages; determined the timing of influenza A and B epidemics; compared the age distribution of B/Victoria and B/Yamagata cases; and evaluated the frequency of lineage-level mismatch for the trivalent vaccine. The median proportion of influenza cases caused by influenza B virus was 23.4%, with a tendency (borderline statistical significance, p = 0.060) to be higher in tropical vs. temperate countries. Influenza B was the dominant virus type in about one every seven seasons. In temperate countries, influenza B epidemics occurred on average three weeks later than influenza A epidemics; no consistent pattern emerged in the tropics. The two B lineages caused a comparable proportion of influenza B cases globally, however the B/Yamagata was more frequent in temperate countries, and the B/Victoria in the tropics (p = 0.048). B/Yamagata patients were significantly older than B/Victoria patients in almost all countries. A lineage-level vaccine mismatch was observed in over 40% of seasons in temperate countries and in 30% of seasons in the tropics. The type B virus caused a substantial proportion of influenza infections globally in the 21st century, and its two virus lineages differed in terms of age and geographical distribution of patients. These findings will help inform health policy decisions aiming to reduce disease burden associated with seasonal influenza.
Klíčová slova:
Medicine and health sciences – Infectious diseases – Viral diseases – Influenza – Infectious disease control – Vaccines – Pathology and laboratory medicine – Pathogens – Influenza B virus – Biology and life sciences – Organisms – Viruses – RNA viruses – Orthomyxoviruses – Influenza viruses – Influenza A virus – Microbiology – Medical microbiology – Microbial pathogens – Viral pathogens – Population biology – Population metrics – Age distribution – Earth sciences – Geography – Geographic areas – Northern Hemisphere – Southern Hemisphere
Zdroje
1. Iuliano AD, Roguski KM, Chang HH, Muscatello DJ, Palekar R, Tempia S, et al. Estimates of global seasonal influenza-associated respiratory mortality: a modelling study. Lancet. 2018;391(10127):1285–1300. doi: 10.1016/S0140-6736(17)33293-2 29248255
2. Rolfes MA, Foppa IM, Garg S, Flannery B, Brammer L, Singleton JAet al. Annual estimates of the burden of seasonal influenza in the United States: A tool for strengthening influenza surveillance and preparedness. Influenza Other Respir Viruses. 2018;12(1):132–137. doi: 10.1111/irv.12486 29446233
3. Cassini A, Colzani E, Pini A, Mangen MJ, Plass D, McDonald SA, et al. Impact of infectious diseases on population health using incidence-based disability-adjusted life years (DALYs): results from the Burden of Communicable Diseases in Europe study, European Union and European Economic Area countries, 2009 to 2013. Euro Surveill. 2018;23(16).
4. Lee VJ, Ho ZJM, Goh EH, Campbell H, Cohen C, Cozza V, et al. Advances in measuring influenza burden of disease. Influenza Other Respir Viruses. 2018;12(1):3–9. doi: 10.1111/irv.12533 29460425
5. Paul Glezen W, Schmier JK, Kuehn CM, Ryan KJ, Oxford J. The burden of influenza B: a structured literature review. Am J Public Health. 2013;103(3):e43–51. doi: 10.2105/AJPH.2012.301137 23327249
6. Tafalla M, Buijssen M, Geets R, Vonk Noordegraaf-Schouten M. A comprehensive review of the epidemiology and disease burden of Influenza B in 9 European countries. Hum Vaccin Immunother. 2016;12(4):993–1002. doi: 10.1080/21645515.2015.1111494 26890005
7. Rota PA, Wallis TR, Harmon MW, Rota JS, Kendal AP, Nerome K. Cocirculation of two distinct evolutionary lineages of influenza type B virus since 1983. Virology. 1990;175(1):59–68. doi: 10.1016/0042-6822(90)90186-u 2309452
8. Paiva TM, Benega MA, Silva DB, Santos KC, Cruz AS, Hortenci MF, et al. Evolutionary pattern of reemerging influenza B/Victoria lineage viruses in São Paulo, Brazil, 1996–2012: Implications for vaccine composition strategy. J Med Virol. 2013;85(11):1983–9. doi: 10.1002/jmv.23684 23926069
9. Jennings L, Huang QS, Barr I, Lee PI, Kim WJ, Buchy P, et al. Literature review of the epidemiology of influenza B disease in 15 countries in the Asia-Pacific region. Influenza Other Respir Viruses. 2018;12(3):383–411. doi: 10.1111/irv.12522 29127742
10. Mertz D, Kim TH, Johnstone J, Lam PP, Science M, Kuster SP, et al. Populations at risk for severe or complicated influenza illness: systematic review and meta-analysis. BMJ. 2013;347:f5061. doi: 10.1136/bmj.f5061 23974637
11. Caini S, Schellevis F, El-Guerche Séblain C, Paget J. Important changes in the timing of influenza epidemics in the WHO European Region over the past 20 years: virological surveillance 1996 to 2016. Euro Surveill. 2018;23(1).
12. Tricco AC, Chit A, Soobiah C, Hallett D, Meier G, Chen MH, et al. Comparing influenza vaccine efficacy against mismatched and matched strains: a systematic review and meta-analysis. BMC Med. 2013;11:153. doi: 10.1186/1741-7015-11-153 23800265
13. Heikkinen T, Ikonen N, Ziegler T. Impact of influenza B lineage-level mismatch between trivalent seasonal influenza vaccines and circulating viruses, 1999–2012. Clin Infect Dis. 2014;59(11):1519–24. doi: 10.1093/cid/ciu664 25139969
14. Caini S, Huang QS, Ciblak MA, Kusznierz G, Owen R, Wangchuk S, et al. Epidemiological and virological characteristics of influenza B: results of the Global Influenza B Study. Influenza Other Respir Viruses. 2015;9 Suppl 1:3–12.
15. de Boer PT, van Maanen BM, Damm O, Ultsch B, Dolk FCK, Crépey P, et al. A systematic review of the health economic consequences of quadrivalent influenza vaccination. Expert Rev Pharmacoecon Outcomes Res. 2017;17(3):249–265. doi: 10.1080/14737167.2017.1343145 28613092
16. Sočan M, Prosenc K, Učakar V, Berginc N. A comparison of the demographic and clinical characteristics of laboratory-confirmed influenza B Yamagata and Victoria lineage infection. J Clin Virol. 2014;61(1):156–60. doi: 10.1016/j.jcv.2014.06.018 25034374
17. Le TT, Pham TH, Pham TH, Nguyen le KH, Nguyen CT, Hoang VM, et al. Circulation of influenza B lineages in northern Viet Nam, 2007–2014. Western Pac Surveill Response J. 2015;6(4):17–23. doi: 10.5365/WPSAR.2015.6.1.022 26798557
18. Xu C, Chan KH, Tsang TK, Fang VJ, Fung RO, Ip DK, et al. Comparative epidemiology of influenza B Yamagata- and Victoria-lineage viruses in households. Am J Epidemiol. 2015;182(8):705–13. doi: 10.1093/aje/kwv110 26400854
19. Barr IG, Vijaykrishna D, Sullivan SG. Differential age susceptibility to influenza B/Victoria lineage viruses in the 2015 Australian influenza season. Euro Surveill. 2016;21(4).
20. Seleka M, Treurnicht FK, Tempia S, Hellferscee O, Mtshali S, Cohen AL, et al. Epidemiology of influenza B/Yamagata and B/Victoria lineages in South Africa, 2005–2014. PLoS One. 2017;12(5):e0177655. doi: 10.1371/journal.pone.0177655 28542324
21. Moa AM, Muscatello DJ, Turner RM, MacIntyre CR. Epidemiology of influenza B in Australia: 2001–2014 influenza seasons. Influenza Other Respir Viruses. 2017;11(2):102–109. doi: 10.1111/irv.12432 27650482
22. Lapinscki B, Pereira LA, Nogueira MB, Vidal LR, Riediger I, Debur MC, et al. Molecular epidemiology of influenza B virus and implications in immunization strategy, Southern Brazil. Vaccine. 2018;36(1):107–113. doi: 10.1016/j.vaccine.2017.11.033 29174679
23. Caini S, Andrade W, Badur S, Balmaseda A, Barakat A, Bella A, et al. Temporal patterns of influenza A and B in tropical and temperate countries: what are the lessons for influenza vaccination? PLoS One. 2016;11(3):e0152310. doi: 10.1371/journal.pone.0152310 27031105
24. Caini S, Spreeuwenberg P, Kusznierz GF, Rudi JM, Owen R, Pennington K, et al. Distribution of influenza virus types by age using case-based global surveillance data from twenty-nine countries, 1999–2014. BMC Infect Dis. 2018;18(1):269. doi: 10.1186/s12879-018-3181-y 29884140
25. Central Intelligence Agency. The World Factbook. Available from https://www.cia.gov/library/publications/the-world-factbook/ Cited 20 June 2018
26. Alonso WJ, McCormick BJ. EPIPOI: a user-friendly analytical tool for the extraction and visualization of temporal parameters from epidemiological time series. BMC Public Health. 2012;12(1):982.
27. World Health Organization. Recommendations on the composition of influenza virus vaccines. http://www.who.int/influenza/vaccines/virus/recommendations/en/ Cited 18 June 2018
28. World Health Organization. Which vaccine formulation to use–Northern or Southern hemisphere? http://www.who.int/influenza/vaccines/tropics/vaccination_formulation/en/ Cited 18 June 2018
29. Hirve S, Lambach P, Paget J, Vandemaele K, Fitzner J, Zhang W. Seasonal influenza vaccine policy, use and effectiveness in the tropics and subtropics—a systematic literature review. Influenza Other Respir Viruses. 2016;10(4):254–67. doi: 10.1111/irv.12374 26842617
30. Mosnier A, Caini S, Daviaud I, Bensoussan JL, Stoll-Keller F, Bui TT, et al. Ten influenza seasons in France: distribution and timing of influenza A and B circulation, 2003–2013. BMC Infect Dis. 2015;15:357. doi: 10.1186/s12879-015-1056-z 26289794
31. Barros EN, Cintra O, Rossetto E, Freitas L, Colindres R. Patterns of influenza B circulation in Brazil and its relevance to seasonal vaccine composition. Braz J Infect Dis. 2016;20(1):81–90. doi: 10.1016/j.bjid.2015.09.009 26626166
32. Pan Y, Zhang Y, Yang P, Qian H, Shi W, Wu S, et al. Epidemiological and phylogenetic characteristics of influenza B infection in severe acute respiratory infection cases in Beijing, 2014 to 2015. Medicine (Baltimore). 2015;94(52):e2399.
33. van Asten L, Bijkerk P, Fanoy E, van Ginkel A, Suijkerbuijk A, van der Hoek W, et al. Early occurrence of influenza A epidemics coincided with changes in occurrence of other respiratory virus infections. Influenza Other Respir Viruses. 2016;10(1):14–26. doi: 10.1111/irv.12348 26369646
34. Caini S, Alonso WJ, Séblain CE, Schellevis F, Paget J. The spatiotemporal characteristics of influenza A and B in the WHO European Region: can one define influenza transmission zones in Europe? Euro Surveill. 2017;22(35).
35. Laurie KL, Guarnaccia TA, Carolan LA, Yan AW, Aban M, Petrie S, et al. Interval between infections and viral hierarchy are determinants of viral interference following influenza virus infection in a ferret model. J Infect Dis. 2015;212(11):1701–10. doi: 10.1093/infdis/jiv260 25943206
36. Belshe RB, Coelingh K, Ambrose CS, Woo JC, Wu X. Efficacy of live attenuated influenza vaccine in children against influenza B viruses by lineage and antigenic similarity. Vaccine. 2010;28(9):2149–56. doi: 10.1016/j.vaccine.2009.11.068 20003926
37. de Boer PT, Kelso JK, Halder N, Nguyen TP, Moyes J, Cohen C, et al. The cost-effectiveness of trivalent and quadrivalent influenza vaccination in communities in South Africa, Vietnam and Australia. Vaccine. 2018;36(7):997–1007. doi: 10.1016/j.vaccine.2017.12.073 29373192
38. Tamerius JD, Shaman J, Alonso WJ, Bloom-Feshbach K, Uejio CK, Comrie A, et al. Environmental predictors of seasonal influenza epidemics across temperate and tropical climates. PLoS Pathog. 2013;9(3):e1003194. doi: 10.1371/journal.ppat.1003194 23505366
39. Lowen AC, Steel J. Roles of humidity and temperature in shaping influenza seasonality. J Virol. 2014;88(14):7692–5. doi: 10.1128/JVI.03544-13 24789791
40. Vijaykrishna D, Holmes EC, Joseph U, Fourment M, Su YC, Halpin R, et al. The contrasting phylodynamics of human influenza B viruses. Elife. 2015;4:e05055. doi: 10.7554/eLife.05055 25594904
41. Nyirenda M, Omori R, Tessmer HL, Arimura H, Ito K. Estimating the lineage dynamics of human influenza B viruses. PLoS One. 2016;11(11):e0166107. doi: 10.1371/journal.pone.0166107 27829058
42. Skowronski DM, Hottes TS, De Serres G, Ward BJ, Janjua NZ, Sabaiduc S, et al. Influenza B/Victoria antigen induces strong recall of B/Yamagata but lower B/Victoria response in children primed with two doses of B/Yamagata. Pediatr Infect Dis J. 2011;30(10):833–9. doi: 10.1097/INF.0b013e31822db4dc 21857263
43. Adlhoch C, Snacken R, Melidou A, Ionescu S, Penttinen; The European Influenza Surveillance Network. Dominant influenza A(H3N2) and B/Yamagata virus circulation in EU/EEA, 2016/17 and 2017/18 seasons, respectively. Euro Surveill. 2018;23(13).
Článek vyšel v časopise
PLOS One
2019 Číslo 9
- Proč se v Česku šíří několik „vymýcených“ infekcí najednou? Ptáme se odborníků
- ADHD jako evoluční výhoda? Výzkum se zaměřil na lovce a sběrače
- Případ Bulovka: Jak postupují jiné nemocnice, aby podobným tragédiím zabránily?
- Metamizol jako analgetikum první volby: kdy, pro koho, jak a proč?
- Není statin jako statin aneb praktický přehled rozdílů jednotlivých molekul
Nejčtenější v tomto čísle
- Graviola (Annona muricata) attenuates behavioural alterations and testicular oxidative stress induced by streptozotocin in diabetic rats
- CH(II), a cerebroprotein hydrolysate, exhibits potential neuro-protective effect on Alzheimer’s disease
- Comparison between Aptima Assays (Hologic) and the Allplex STI Essential Assay (Seegene) for the diagnosis of Sexually transmitted infections
- Assessment of glucose-6-phosphate dehydrogenase activity using CareStart G6PD rapid diagnostic test and associated genetic variants in Plasmodium vivax malaria endemic setting in Mauritania
Zvyšte si kvalifikaci online z pohodlí domova
Všechny kurzy